Clinical Efficacy of Modified Banxia Baizhu Tianma Decoction in Treating Metabolic Hypertension with Dyslipidemia Based on State-Target Differentiation and Treatment Theory
10.13359/j.cnki.gzxbtcm.2025.09.007
- VernacularTitle:基于态靶辨治探究半夏白术天麻汤加味治疗代谢性高血压合并血脂紊乱的临床疗效
- Author:
Yingxin ZHANG
1
;
Fusheng YAO
;
Ping LI
Author Information
1. 广州中医药大学研究生院,广东 广州 510006
- Keywords:
state-target differentiation and treatment;
metabolic hypertension;
dyslipidemia;
phlegm-damp obstruction syndrome;
Banxia Baizhu Tianma Decoction;
blood pressure;
body mass index;
fasting blood glucose;
serum uric acid
- From:
Journal of Guangzhou University of Traditional Chinese Medicine
2025;42(9):2133-2139
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of modified Banxia Baizhu Tianma Decoction(BBTD)on blood pressure and lipid metabolism in patients with metabolic hypertension and dyslipidemia of phlegm-damp obstruction syndrome,guided by Professor Tong Xiaolin's"state-target differentiation and treatment"theory.Methods Sixty eligible patients treated at Chongqing Beibei Hospital of Traditional Chinese Medicine from February 2024 to February 2025 were randomly assigned to treatment group(n=30,receiving conventional therapy plus modified BBTD)and control group(n=30,conventional therapy alone)for 4 weeks.The changes in blood pressure,lipid profiles,body mass index(BMI),fasting blood glucose(FBG),serum uric acid(SUA)were observed,and the antihypertensive efficacy and traditional Chinese medicine(TCM)syndrome efficacy were evaluated.Results(1)Regarding participant dropout,during the study,2 cases in the treatment group were lost to follow-up,while no dropouts occurred in the control group.Ultimately,58 patients were included in the efficacy analysis(28 in the treatment group,30 in the control group).(2)In terms of antihypertensive efficacy,after 4 weeks of treatment,the total effective rate was 92.86％(26/28)in the treatment group versus 36.67％(11/30)in the control group.The intergroup comparison(by chi-square test)demonstrated significantly superior antihypertensive efficacy in the treatment group(P＜0.05).(3)For TCM syndrome efficacy,the marked improvement rate and total effective rate in the treatment group were 60.71％(17/28)and 92.86％(26/28)respectively,compared to 0.00％(0/30)and 33.33％(10/30)in the control group.The treatment group showed significantly better outcomes in marked improvement rate(by chi-square test),total effective rate(by chi-square test),and overall efficacy(by rank-sum test)(all P＜0.05).(4)Regarding blood pressure,post-treatment systolic blood pressure(SBP)and diastolic blood pressure(DBP)were significantly decreased in the treatment group(P＜0.05)but remained unchanged in the control group(P＞0.05).The treatment group exhibited significantly greater reductions in both SBP and DBP compared to controls(P＜0.05).(5)For lipid profiles,the treatment group showed significant post-treatment reductions in total cholesterol(TC),triglycerides(TG),and low-density lipoprotein cholesterol(LDL-C)(P＜0.05).The control group demonstrated increased TG(P＜0.05),with nonsignificant decreases in TC and LDL-C,and a slight increase of HDL-C(P＞0.05).The treatment group achieved significantly greater TC and TG reductions versus controls(P＜0.05).(6)The treatment group showed decreased BMI,fasting glucose,and serum uric acid(P＜0.05),whereas the control group had unchanged BMI and fasting glucose(P＞0.05)but increased uric acid(P＜0.05).The treatment group's reductions in fasting glucose and uric acid were significantly superior to those of control group(P＜0.05).Conclusion State-target-guided modified BBTD effectively treats metabolic hypertension with dyslipidemia of phlegm-damp obstruction syndrome,demonstrating comprehensive metabolic benefits beyond blood pressure control.
